NEW YORK (GenomeWeb) – BioFire Diagnostics today said that it has inked a purchasing agreement to provide multi-target molecular diagnostic tests for HealthTrust's nearly 1,400 member healthcare facilities.
The agreement provides HealthTrust's members with access to BioFire's FilmArray molecular diagnostic system and its portfolio of infectious disease assays including tests for respiratory, bloodstream, and gastrointestinal infections. According to the Salt lake City-based subsidiary of BioMérieux, its each panel that runs on its FilmArray platform simultaneously tests for 20-plus viral, bacterial, parasitic, yeast, and/or antibiotic resistance targets, and provides a one-hour turnaround time.
Randy Rasmussen, BioMérieux corporate vice president of Molecular Biology and CEO of BioFire Diagnostics, said that the agreement, which became effective on June 1, "presents a strong opportunity to rapidly expand the FilmArray customer base to a greater number of hospitals, especially across the nation's leading providers of acute healthcare."
HealthTrust, legally known as HealthTrust Purchasing Group, provides cost management services to healthcare businesses. In addition to the approximately 1,400 acute care facilities, the Brentwood, Tenn.-based company serves 800 ambulatory surgery centers and members in more than 10,600 other locations, including physician practices, long-term care, and alternate care sites.
HealthTrust recently inked a similar molecular diagnostics purchasing deal with Nanosphere.